RhumbLine Advisers’s Serina Therapeutics SER Stock Holding History

RhumbLine Advisers’s Portfolio SER Stock Details SER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-606	Closed	-$20K	–	3122
2020 Q1	$20K	Hold	606	–	–	﹤0.01%	2905
2019 Q4	$39K	Sell	606 -9	-1%	-$486	﹤0.01%	2922
2019 Q3	$42K	Sell	615 -6	-1%	-$569	﹤0.01%	2933
2019 Q2	$80K	Buy	621 +235	+61%	+$31.8K	﹤0.01%	2939
2019 Q1	$55K	Buy	386 +22	+6%	+$3.22K	﹤0.01%	2911
2018 Q4	$38K	Buy	+364	New	+$46.3K	﹤0.01%	2959

Other funds holding SER

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OMC

Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

RhumbLine Advisers's SER Position: Q2 2020 in Review

RhumbLine Advisers sold out of Serina Therapeutics (SER) in Q2 2020, closing a stake of 606 shares — an estimated $20K sold.

RhumbLine Advisers first reported a position in SER in Q4 2018 and held it in 6 quarters. The position peaked at $80K in Q2 2019. 48 funds tracked by Wall St. Rank hold SER as of Q2 2020.

RhumbLine Advisers reported no remaining Serina Therapeutics position as of Q2 2020 after selling out during the quarter.
RhumbLine Advisers sold 606 Serina Therapeutics shares in Q2 2020, an estimated $20K.
RhumbLine Advisers first reported a position in Serina Therapeutics in Q4 2018 and held it in 6 quarters.
RhumbLine Advisers's Serina Therapeutics position peaked at $80K in Q2 2019.
48 funds tracked by Wall St. Rank held Serina Therapeutics as of Q2 2020.

Based on RhumbLine Advisers's 13F filing for Q2 2020, filed 13 Aug 2020.